Literature DB >> 14581282

High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy.

Y H Park, B-Y Ryoo, H J Lee, S A Kim, J-H Chung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14581282     DOI： 10.1093/annonc/mdg446

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Validation of the Japanese version of HFS-14, a disease-specific quality of life scale for patients suffering from hand-foot syndrome.

Authors:  Naoko Mikoshiba; Noriko Yamamoto-Mitani; Kazuki Sato; Yoshinari Asaoka; Takamasa Ohki; Misato Ohata; Mitsunori Miyashita
Journal:  Support Care Cancer       Date:  2015-02-08       Impact factor: 3.603

2.  [Hand-foot syndrome with capecitabine therapy].

Authors:  A Marini; U R Hengge
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

3.  Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study.

Authors:  Mark Hackbarth; Norbert Haas; Christina Fotopoulou; Werner Lichtenegger; Jalid Sehouli
Journal:  Support Care Cancer       Date:  2007-08-07       Impact factor: 3.603
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.